Meyeon Park, MD, MAS

Director of the Polycystic Kidney Disease (PKD) Center of Excellence
Nephrologist

Dr. Meyeon Park is a nephrologist who sees patients with all presentations of hypertension and kidney disease. She has a special focus on polycystic kidney disease and is the director of UCSF's Polycystic Kidney Disease (PKD) Center of Excellence.

Park's research explores how heart disease and kidney disease influence each other. She is particularly interested in learning how lifestyle changes can help individuals with PKD.

Park earned her medical degree at the Perelman School of Medicine at the University of Pennsylvania. She then completed a residency in internal medicine at the Yale School of Medicine, followed by a residency in nephrology at UCSF. She also has a master of advanced studies degree in clinical research from UCSF.

Park is an assistant professor in residence at UCSF and a member of the American Society of Nephrology.

Clinics

Nephrology and Hypertension Faculty Practice
400 Parnassus Ave., B1 Plaza Level
San Francisco, CA 94143-0532
Phone: (415) 353-2507
Fax: (415) 353-2530

Hours: Monday to Friday
8 a.m. – 5 p.m.

Polycystic Kidney Disease (PKD) Center of Excellence
400 Parnassus Ave., B1 Plaza Level
San Francisco, CA 94143
Phone: (415) 514-2381

Hours: Monday to Friday,
9 a.m. - 5 p.m.

Board Certification

Internal Medicine, American Board of Internal Medicine
Nephrology, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Meyeon Park

Additional Languages

French

Education

Perelman School of Medicine 2006
UCSF, M.A.S., Clinical Research 2012

Residencies

Yale University School of Medicine, Internal Medicine 2009

Fellowships

UCSF, Nephrology 2011

Selected Research and Publications

  1. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. Data Brief. 2017 Oct; 14:366-370.
  2. Tran WC, Huynh D, Chan T, Chesla CA, Park M. Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease. BMC Nephrol. 2017 Jul 05; 18(1):214.
  3. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. Atherosclerosis. 2017 Aug; 263:68-73.
  4. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017 May 08; 12(5):761-771.
  5. Park M, Shlipak MG, Thiessen-Philbrook H, Garg AX, Koyner JL, Coca SG, Parikh CR. Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations. Ann Thorac Surg. 2016 Apr; 101(4):1395-401.
  6. Park M, Shlipak MG, Vittinghoff E, Katz R, Siscovick D, Sarnak M, Lima JA, Hsu CY, Peralta CA. Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Clin Nephrol. 2015 Dec; 84(6):358-63.
  7. Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016 Jul; 27(7):2109-21.
  8. Park M, Kulkarni A, Beatty A, Ganz P, Regan M, Vittinghoff E, Whooley M. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study. Atherosclerosis. 2015 Dec; 243(2):546-52.
  9. Wu EH, Wojciechowski D, Chandran S, Yeh BM, Park M, Westphalen A, Wang ZJ. Prevalence of abdominal aortic calcifications in older living renal donors and its effect on graft function and histology. Transpl Int. 2015 Oct; 28(10):1172-8.
  10. Park M. Islands in the stream: the risk of kidney disease from cardiovascular disease. Am J Kidney Dis. 2015 May; 65(5):647-9.
  11. Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015 Feb 06; 10(2):205-14.
  12. Chong KC, Owens CD, Park M, Alley HF, Boscardin WJ, Conte MS, Gasper WJ, Grenon SM. Relationship between kidney disease and endothelial function in peripheral artery disease. J Vasc Surg. 2014 Dec; 60(6):1605-11.
  13. Park M, Vittinghoff E, Shlipak MG, Mishra R, Whooley M, Bansal N. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study. Am Heart J. 2014 Dec; 168(6):931-9.e2.
  14. Park M, Hsu CY. An ACE in the hole for patients with advanced chronic kidney disease? JAMA Intern Med. 2014 Mar; 174(3):355-6.
  15. Parikh CR, Butrymowicz I, Yu A, Chinchilli VM, Park M, Hsu CY, Reeves WB, Devarajan P, Kimmel PL, Siew ED, Liu KD. Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis. 2014 Apr; 63(4):567-72.
  16. Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: the Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2014 Jan; 34(1):231-6.
  17. Park M, Vittinghoff E, Liu KD, Shlipak MG, Hsu CY. Urine Biomarkers Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) Have Different Patterns in Heart Failure Exacerbation. Biomark Insights. 2013; 8:15-8.
  18. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012 Oct; 23(10):1725-34.
  19. Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2012 Jul; 7(7):1137-44.
  20. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol. 2010; 31(5):408-18.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.